KannaLife Sciences, Inc. Announces Publication of Its Global PCT Patent Covering Cannabidiol-like Neuroprotective Agents
NEW YORK, Aug. 6, 2015 (GLOBE NEWSWIRE) -- KannaLife Sciences, Inc., a Phyto-Medical Company, announced the publication of its global WIPO/PCT Patent WO2015/106108A2 – 'Novel Functionalized 1,3-Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy'.
It is widely understood that hepatic encephalopathy (HE) and chronic traumatic encephalopathy (CTE) are associated with free radical mediated stress in neurons. Treatments that ameliorate this neural damage will demonstrate improvements in cognitive function, learning, and memory. Cannabidiol (CBD) has potential in treating oxidative stress but has limitations in terms of safety and pharmacokinetics, making the safe delivery of an efficacious dose problematic. KLS-13019 improves upon CBD in terms of neuroprotective potency and safety in hippocampal cultures, and dramatic improvements to oral bioavailability in rats.
Free radical mediated stress and oxidative stress is also known to contribute to additional pathological conditions, including, but not limited to epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). Hence, compounds, such as KannaLife's novel therapeutic agent KLS-13019, may be capable of acting as neuroprotective agents and useful for the treatment of epilepsy, neuropathic pain, traumatic head injury, stroke, Chronic Traumatic Encephalopathy (CTE), Post Cardiac Arrest Hypoxic Ischemic Encephalopathy, Epileptic Encephalopathy, and neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
KannaLife CEO, Dean Petkanas, stated, "We believe our recently published PCT patent application will result in issuance of patents internationally, which will provide exclusivity until at least 2034. This is a testament to hard work, dedication, and professionalism of the KannaLife team in the field of cannabinoid based therapeutics. We are particularly proud of this accomplishment in light of the pioneering research in this field by notable scientists such as Julius Axelrod, Raphael Mechoulam, and Alexandros Makriyiannis."
About KannaLife Sciences, Inc.
KannaLife Sciences, Inc. is a phyto-medical company involved in the research and development of novel therapeutic agents designed to be neuroprotectants and immuno-modulators. KannaLife is currently conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA, for target drug candidates to treat Hepatic Encephalopathy ("HE") and Chronic Traumatic Encephalopathy ("CTE"). HE and CTE are oxidative stress related diseases that affect cognitive and behavioral functions. For more information, visit www.KannaLife.com.
CONTACT: For further information, please contact: Public Relations contact: Andrew Hard Spokesperson CMW Media P. 858-380-5478 email@example.com Corporate contact: KannaLife Sciences, Inc. (516) 669-3219 www.KannaLife.com
Help employers find you! Check out all the jobs and post your resume.